‘It was finally worth it’: Adar Poonawalla thanks Prime Minister Modi, DCGI after Covishield gets final approval
For the CEO of the Serum Institute of India, Adar Poonawalla, the moment of happy new year came on January 3 after the General Controller of Drugs of India on Sunday gave the final go-ahead to Covishield, the vaccine developed by the University. from Oxford and Astrazeneca Pharmaceuticals and manufactured in India by Poonawalla’s. Serum Institute. It received the go-ahead for restricted emergency use in India, after the expert committee on the matter reviewed its data and recommended the vaccine for emergency use.
“Happy New Year everyone! All the risks that @SerumInstIndia took in storing the vaccine have finally paid off. COVISHIELD, India’s first COVID-19 vaccine is approved, safe, effective and ready to roll out in the next few weeks, ”Adar tweeted, thanking Prime Minister Modi, Union Health Minister Dr. Harsh Vardhan, and all other stakeholders including ICMR, DBT, DCGI, Gavi, Gates Foundation, etc.
Even before gaining approval from India’s main drug controller, the Serum Institute of India stockpiled between 40 and 50 million doses of the Covid-19 vaccine, posing a significant risk should the drug regulator reject your application. The world’s largest vaccine manufacturer, by volume it produces, has set a goal of producing around 300 million doses of Covishield by July 2021.
Overall, Serum’s investment in Covishield is around $ 100 million.